In breast cancer cells, glucose metabolism is promoted by β1-integrin signaling through Twist, a regulator of epithelial-mesenchymal transition (EMT) (Yang et al., 2016), while knockdown of Glut1 in breast cancer cells lowers integrin β1 levels followed by reduced Src and FAK expression (Oh et al., 2017). The gene discussed is SLC2A1; the disease is breast carcinoma.